Novo Nordisk Loses Canadian Patent Protection For Blockbuster Diabetes Drug Over Unpaid $450 Fee
Pharmaceutical giant Novo Nordisk forfeited patent protection for semaglutide — the active ingredient in blockbuster diabetes and weight loss drugs Ozempic and Wegovy — in Canada after failing to pay… Weiterlesen »Novo Nordisk Loses Canadian Patent Protection For Blockbuster Diabetes Drug Over Unpaid $450 Fee